Literature DB >> 15542636

Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.

Keith Meyer1, Aster Beyene, Terry L Bowlin, Arnab Basu, Ranjit Ray.   

Abstract

We have previously reported that a pseudotype virus generated by reconstitution of hepatitis C virus (HCV) chimeric envelope glycoprotein E1-G or E2-G on the surface of a temperature-sensitive mutant of vesicular stomatitis virus (VSVts045) interacts independently with mammalian cells to initiate infection. Here, we examined whether coexpression of both of the envelope glycoproteins on pseudotype particles would augment virus infectivity and/or alter the functional properties of the individual subunits. Stable transfectants of baby hamster kidney (BHK) epithelial cells expressing either one or both of the chimeric envelope glycoproteins of HCV on the cell surface were generated. The infectious titer of the VSV pseudotype, derived from a stable cell line incorporating both of the chimeric glycoproteins of HCV, was approximately 4- to 5-fold higher than that of a pseudotype bearing E1-G alone or approximately 25- to 30-fold higher than that of E2-G alone when assayed with a number of mammalian cell lines. Further studies suggested that that the E1-G/E2-G or E2-G pseudotype was more sensitive to the inhibitory effect of heparin than the E1-G pseudotype. Treatment of the E1-G/E2-G pseudotype with a negatively charged sulfated sialyl lipid (NMSO3) displayed a approximately 4-fold-higher sensitivity to neutralization than pseudotypes with either of the two individual glycoproteins. In contrast, VSVts045, used as a backbone for the generation of pseudotypes, displayed at least 20-fold-higher sensitivity to NMSO3-mediated inhibition of virus plaque formation. The effect of low-density lipoprotein on the E1-G pseudotype was greater than that apparent for the E1-G/E2-G pseudotype. The treatment of cells with monoclonal antibodies to CD81 displayed an inhibitory effect upon the pseudotype with E1-G/E2-G or with E2-G alone. Taken together, our results indicate that the HCV E1 and E2 glycoproteins have separable functional properties and that the presence of these two envelope glycoproteins on VSV/HCV pseudotype particles increases infectious titer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542636      PMCID: PMC524985          DOI: 10.1128/JVI.78.23.12838-12847.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Inhibition of P-selectin-mediated cell adhesion by a sulfated derivative of sialic acid.

Authors:  Tomonori Shodai; Junsuke Suzuki; Sanae Kudo; Saotomo Itoh; Masaki Terada; Shuji Fujita; Hajime Shimazu; Tsutomu Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2003-12-19       Impact factor: 3.575

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

Review 3.  Proteoglycan core protein families.

Authors:  J R Hassell; J H Kimura; V C Hascall
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

4.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Authors:  Keith Meyer; Arnab Basu; Craig T Przysiecki; L Martin Lagging; Adrian M Di Bisceglie; Anthony J Conley; Ranjit Ray
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

8.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.

Authors:  Aster Beyene; Arnab Basu; Keith Meyer; Ranjit Ray
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

10.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  11 in total

1.  Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.

Authors:  Budhaditya Mazumdar; Arup Banerjee; Keith Meyer; Ranjit Ray
Journal:  Hepatology       Date:  2011-07-25       Impact factor: 17.425

2.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Authors:  Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

3.  ISG56 and IFITM1 proteins inhibit hepatitis C virus replication.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Hangeun Kim; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

4.  Generation of infectious hepatitis C virus in immortalized human hepatocytes.

Authors:  Tatsuo Kanda; Arnab Basu; Robert Steele; Takaji Wakita; Jan S Ryerse; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

Review 6.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Authors:  Ranjit Ray; Keith Meyer; Arup Banerjee; Arnab Basu; Stephen Coates; Sergio Abrignani; Michael Houghton; Sharon E Frey; Robert B Belshe
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

8.  Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.

Authors:  Arnab Basu; Tatsuo Kanda; Aster Beyene; Kousuke Saito; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Oncogenic potential of hepatitis C virus proteins.

Authors:  Arup Banerjee; Ratna B Ray; Ranjit Ray
Journal:  Viruses       Date:  2010-09-27       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.